CMA Recommendations on Vaccine Equity and Intellectual Property

https://policybase.cma.ca/link/policy14476

POLICY TYPE  Parliamentary submission
DATE  2022-05-13
TOPICS  Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

https://policybase.cma.ca/link/policy443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE  Parliamentary submission
DATE       2020-08-13
TOPICS     Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image of document page]

[Text in document page]

We are writing to urge your committee to bring into effect necessary measures to ensure adequate supply of drugs in the country during the current pandemic. The problem is acute, and the situation requires urgent attention.

The shortage of drugs is a critical issue that affects the health of the population. The current pandemic has highlighted the importance of having a robust supply chain. It is imperative that measures are put in place to ensure the continuity of drug supply during the pandemic.

In view of this, we urge your committee to consider the following recommendations:

1. Increase investment in the pharmaceutical industry to ensure a stable supply of drugs.
2. Establish a national drug reserve to ensure that there is a buffer supply in case of shortages.
3. Strengthen the regulatory framework to ensure that the quality of drugs is maintained.
4. Encourage the local production of essential drugs to reduce the dependence on imported products.
5. Foster international collaboration to ensure that essential drugs are available in the country.

We believe that these recommendations will help address the drug shortage issue during the pandemic.

Thank you for your attention to this matter.

Sincerely,

[Signature]

[Name]

Canadian Medical Association

[Date]
Authorizing Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE: Policy document
LAST REVIEWED: 2019-03-03
DATE: 2010-12-04
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

Cannabis for Medical Purposes

CMA POLICY

Cannabis for Medical Purposes

Policy recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis for the purpose of improving the current evidence base, including the efficacy and safety of cannabis, and the potential for reducing the risk of dependency.

2. Develop a regulatory framework for cannabis that is consistent with other prescription medications, and that takes into account the unique properties of cannabis.

3. Increase support for the development of clinical trials for cannabis, and for the dissemination of results from these trials.

4. Develop a national pharmacovigilance system for cannabis, to monitor the safety and efficacy of cannabis use in Canada.

5. Increase support for research into the potential medical applications of cannabis, and for the development of new treatments for conditions that have been shown to benefit from cannabis use.

6. Develop a national training program for healthcare providers on the safe and effective use of cannabis for medical purposes.

7. Increase support for the development of guidelines for the safe and effective use of cannabis for medical purposes, and for the dissemination of these guidelines to healthcare providers.

8. Increase support for the development of educational programs for patients on the safe and effective use of cannabis for medical purposes.

9. Develop a national monitoring and evaluation system for the use of cannabis for medical purposes, to monitor the impact of cannabis use on public health and healthcare systems.

10. Increase support for the development of research into the potential long-term effects of cannabis use on public health and healthcare systems.

The CMA endorses the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis for the purpose of improving the current evidence base, including the efficacy and safety of cannabis, and the potential for reducing the risk of dependency.

2. Develop a regulatory framework for cannabis that is consistent with other prescription medications, and that takes into account the unique properties of cannabis.

3. Increase support for the development of clinical trials for cannabis, and for the dissemination of results from these trials.

4. Develop a national pharmacovigilance system for cannabis, to monitor the safety and efficacy of cannabis use in Canada.

5. Increase support for research into the potential medical applications of cannabis, and for the development of new treatments for conditions that have been shown to benefit from cannabis use.

6. Develop a national training program for healthcare providers on the safe and effective use of cannabis for medical purposes.

7. Increase support for the development of guidelines for the safe and effective use of cannabis for medical purposes, and for the dissemination of these guidelines to healthcare providers.

8. Increase support for the development of educational programs for patients on the safe and effective use of cannabis for medical purposes.

9. Develop a national monitoring and evaluation system for the use of cannabis for medical purposes, to monitor the impact of cannabis use on public health and healthcare systems.

10. Increase support for the development of research into the potential long-term effects of cannabis use on public health and healthcare systems.
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2011-05-28
REPLACES  Medication use and seniors
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE          Response to consultation
DATE                2019-02-20
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs
                          Population health, health equity, public health

Documents
<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-12-04</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

**Documents**

CMA response:

HEALTH CANADA CONSULTATION ON CANADIAN DRUGS AND SUBSTANCES STRATEGY

November 1, 2018
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE       Response to consultation
DATE              2018-10-02
TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE Response to consultation
DATE 2018-09-06
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE          Policy endorsement
DATE                2018-08-30
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE  Response to consultation
DATE  2018-08-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE        Response to consultation
DATE              2018-07-18
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA response:

HEALTH CANADA CONSULTATION ON RESTRICTION OF MARKETING AND ADVERTISING OF OPIOIDS

Jun 14, 2018
Consultation on proposed front-of-package labelling

https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Proposed approach to the regulation of cannabis

https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE: Response to consultation
DATE: 2017-12-07
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017